Noureddin Nabil, Copur-Dahi Nedret, Loomba Rohit
MASLD Research Center, University of California at San Diego, La Jolla, California, USA.
Division of Gastroenterology & Hepatology, University of California at San Diego, La Jolla, California, USA.
Aliment Pharmacol Ther. 2024 Jun;59 Suppl 1(Suppl 1):S41-S51. doi: 10.1111/apt.17752.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease. Its prevalence is increasing with the epidemic of obesity and metabolic syndrome. MASLD progression into metabolic dysfunction-associated steatohepatitis (MASH) and advanced fibrosis may lead to decompensated cirrhosis and development of liver-related events, hepatocellular carcinoma and death. Monitoring disease progression is critical in decreasing morbidity, mortality, need for transplant and economic burden. Assessing for treatment response once FDA-approved medications are available is still an unmet clinical need.
To explore the most up-to-date literature on testing used for monitoring disease progression and treatment response METHODS: We searched PubMed from inception to 15 August 2023, using the following MeSH terms: 'MASLD', 'Metabolic dysfunction-associated steatotic liver disease', 'MASH', 'metabolic dysfunction-associated steatohepatitis', 'Non-Alcoholic Fatty Liver Disease', 'NAFLD', 'non-alcoholic steatohepatitis', 'NASH', 'Biomarkers', 'clinical trial'. Articles were also identified through searches of the authors' files. The final reference list was generated based on originality and relevance to this review's broad scope, considering only papers published in English.
We have cited 101 references in this review detailing methods to monitor MASLD disease progression and treatment response.
Various biomarkers can be used in different care settings to monitor disease progression. Further research is needed to validate noninvasive tests more effectively.
代谢功能障碍相关脂肪性肝病（MASLD）是慢性肝病最常见的病因。其患病率随着肥胖和代谢综合征的流行而增加。MASLD进展为代谢功能障碍相关脂肪性肝炎（MASH）和肝纤维化可能导致失代偿期肝硬化以及肝脏相关事件、肝细胞癌和死亡的发生。监测疾病进展对于降低发病率、死亡率、移植需求和经济负担至关重要。在有美国食品药品监督管理局（FDA）批准的药物可用时，评估治疗反应仍是一项未满足的临床需求。
探索用于监测疾病进展和治疗反应的最新检测相关文献。
我们检索了从创刊到2023年8月15日的PubMed，使用了以下医学主题词：“MASLD”、“代谢功能障碍相关脂肪性肝病”、“MASH”、“代谢功能障碍相关脂肪性肝炎”、“非酒精性脂肪性肝病”、“NAFLD”、“非酒精性脂肪性肝炎”、“NASH”、“生物标志物”、“临床试验”。还通过检索作者的文件来识别文章。最终的参考文献列表是根据原创性以及与本综述广泛范围的相关性生成的，仅考虑以英文发表的论文。
我们在本综述中引用了101篇参考文献，详细介绍了监测MASLD疾病进展和治疗反应的方法。
各种生物标志物可用于不同的护理环境中监测疾病进展。需要进一步研究以更有效地验证非侵入性检测。
